Piper Sandler Issues Positive Forecast for Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price

Amneal Pharmaceuticals (NASDAQ:AMRX) had its target price boosted by Piper Sandler from $9.00 to $11.00 in a research report sent to investors on Monday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other analysts have also recently weighed in on AMRX. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target for the company in a research report on Friday, September 6th. Truist Financial boosted their price objective on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday, October 2nd. Finally, Barclays increased their target price on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Amneal Pharmaceuticals has an average rating of “Buy” and an average target price of $10.00.

Amneal Pharmaceuticals Stock Down 2.4 %

Shares of AMRX stock opened at $9.03 on Monday. Amneal Pharmaceuticals has a fifty-two week low of $4.16 and a fifty-two week high of $9.48. The firm’s 50 day moving average price is $8.55 and its two-hundred day moving average price is $7.61.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Profund Advisors LLC boosted its holdings in Amneal Pharmaceuticals by 8.1% in the second quarter. Profund Advisors LLC now owns 22,522 shares of the company’s stock valued at $143,000 after purchasing an additional 1,680 shares during the last quarter. ProShare Advisors LLC raised its position in shares of Amneal Pharmaceuticals by 8.6% in the 1st quarter. ProShare Advisors LLC now owns 21,902 shares of the company’s stock valued at $133,000 after purchasing an additional 1,726 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Amneal Pharmaceuticals by 18.8% during the 1st quarter. SG Americas Securities LLC now owns 20,112 shares of the company’s stock valued at $122,000 after buying an additional 3,177 shares during the last quarter. Rothschild Investment LLC purchased a new position in shares of Amneal Pharmaceuticals during the 2nd quarter valued at approximately $26,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Amneal Pharmaceuticals by 13.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,952 shares of the company’s stock worth $222,000 after buying an additional 4,115 shares in the last quarter. 31.82% of the stock is owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.